Summit Therapeutics Inc. — Form 8-K
Filed September 15, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Summit presented updated June 2026 data from the Phase III HARMONi trial at WCLC 2026, showing ivonescimab plus chemotherapy achieved a hazard ratio of 0.76 (95% CI: 0.61–0.95; p=0.0151) for overall survival in the global population, with median OS of 16.8 months vs. 14.0 months for placebo (n=219 per arm). Western patients (n=83 ivonescimab, n=82 placebo) demonstrated consistent results with HR 0.76 (95% CI: 0.52–1.10) at median follow-up of 23.2 months. No new safety signals were observed. The FDA BLA has a PDUFA goal date of November 14, 2026.
Why this rating
Positive Phase III efficacy data with statistical significance achieved and consistent geography supports likely regulatory approval. Material for ~$2.5B company; ivonescimab is lead candidate.
Tradability signal
NO TRADE
No trade: positive news with only -0.6% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: +0.42% over 4 hrs, n=73). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $18.30 ▼ 0.35% | at our read · unknown $18.36 | +10 min · unknown $18.30 ▼ 0.38% | +30 min · unknown $17.82 ▼ 2.99% | +1 hr · unknown $17.81 ▼ 3.02% | +4 hrs pending |
The stock had already moved +0.36% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.